Citigroup Inc. : Back on price levels to sell
Entry price | Target | Stop-loss | Potential |
---|
US$47.5 |
US$35.4 |
US$51.5 |
+25.47% |
---|
Citigroup Inc. shares can be expected to top out below the medium term resistance at 51.04 USD. The timing appears attractive to take advantage of a correction below this level.
Strengths● The group's activity appears highly profitable thanks to its outperforming net margins.
● With a P/E ratio at 8.88 for the current year and 6.81 for next year, earnings multiples are highly attractive compared with competitors.
● Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Weaknesses● Technically, the stock approaches a strong medium-term resistance at USD 51.04.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● Analysts covering the stock have recently lowered their earnings forecast.
● For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
● The technical configuration over the long term remains negative on the weekly chart below the resistance level at 56.11 USD
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.